The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Exelixis Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Exelixis Inc.
Approximately 380,000 people in the US were affected by NETs in 2024
A phase 1 clinical trial of the candidate in advanced solid tumours is currently enrolling patients
The decision could benefit approximately 2,287 patients with renal cell carcinoma annually
More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year
Renal cell carcinoma accounts for more than 431,000 new cases and 179,000 deaths each year
Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium
Combination treatment topped Pfizer’s Sutent in phase 3
Detailed results presented at ESMO 2020 virtual congress
First worldwide approval for MET inhibitor
Announces encouraging results after initial trial fail
Another significant bolt-on in oncology
A rapid round-up of pharma, biotech and healthcare news
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology